Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend

Drug firm Alembic Pharmaceuticals Ltd on Friday (May 15) reported a 29% year-on-year rise in consolidated net profit for the fourth quarter, with profit increasing to ₹202 crore from ₹157 crore a year earlier.

Revenue for the quarter rose 4.4% to ₹1,848 crore compared with ₹1,770 crore in the year-ago period. EBITDA declined 16.2% year-on-year to ₹228 crore from ₹272 crore, while EBITDA margin narrowed to 12.3% from 15.4% last year.

The company’s India-branded business grew 4% year-on-year to ₹568 crore during the quarter. Alembic said the gynaecology, gastrology, ophthalmology and animal healthcare segments delivered encouraging performance. The company launched two new products in the domestic market during the quarter.

Also Read: Alembic Pharma shares rise on USFDA nod for prostate cancer drug with $3 billion estimated market size

International business performance was led by the US formulations segment, which grew 11% year-on-year to ₹564 crore. Alembic launched six products in the US market during the quarter. Revenue from the ex-US generics business stood at ₹369 crore, while the company received four ANDA approvals during the quarter.

Its API business recorded 2% year-on-year growth to ₹347 crore during the quarter.

During the quarter, Alembic also entered the US branded pharmaceuticals market through its step-down wholly owned subsidiary, Alembic Therapeutics, with the commercial launch of Pivya.

The company said Pivya is a first-line oral antibiotic for the treatment of uncomplicated urinary tract infections in women. Alembic said the category has seen limited new product launches for more than a decade.

Also Read: Alembic Pharma gets USFDA nod for Fingolimod capsules; targets $145 million market

Pranav Amin, Managing Director, Alembic Pharmaceuticals, said, "Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments.

We delivered revenue growth across key segments while maintaining healthy pre-R&D operating margins. During the quarter, we marked our entry into the Branded Business in the US, beginning with the launch of Pivya, opening a new avenue for long-term value creation."

The company also recommended a dividend of ₹12 per equity share of face value ₹2 each for shareholders. Shares of Alembic Pharmaceuticals Ltd ended at ₹782.10, down by ₹4.35, or 0.55%, on the BSE.

Also Read: Alembic Pharma receives final US FDA approval for eye inflammation drug